These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37469246)

  • 101. Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC.
    Terashima Y; Matsumoto M; Iida H; Takashima S; Fukuizumi A; Takeuchi S; Miyanaga A; Terasaki Y; Kasahara K; Seike M
    JTO Clin Res Rep; 2023 Nov; 4(11):100578. PubMed ID: 37885809
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab.
    Akashi Y; Yamamoto Y; Hashimoto M; Adomi S; Fujita K; Kiba K; Minami T; Yoshimura K; Hirayama A; Uemura H
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136326
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab.
    Lee RH; Truong A; Wu X; Kang H; Algazi AP; El-Sayed IH; George JR; Heaton CM; Ryan WR; Ha PK; Wai KC
    Head Neck; 2024 Jan; 46(1):129-137. PubMed ID: 37897202
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses.
    Ravi N; Gupta P; Bal A; Prasad KT; Garg M; Kapoor R; Singh N
    Explor Target Antitumor Ther; 2024; 5(3):508-521. PubMed ID: 38966173
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
    Komura K; Tokushige S; Ishida M; Hirosuna K; Yamazaki S; Nishimura K; Ajiro M; Ohno T; Nakamori K; Kinoshita S; Tsujino T; Maenosono R; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Cancer Sci; 2023 Dec; 114(12):4622-4631. PubMed ID: 37752769
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Prognostic value of body mass index for first-line chemoimmunotherapy combinations in advanced non-small cell lung cancer in Chinese population.
    Sun Y; Dang Q; Ge Y; Zhang J; Cheng Q; Sun H; Wang L; Gao A; Sun Y; Li J
    Heliyon; 2024 Jun; 10(11):e31863. PubMed ID: 38841444
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The Combination of Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio Predicts Survival for Non-small Cell Lung Cancer Patients.
    Gong S; Yao X
    Ann Surg Oncol; 2023 Jul; 30(7):4062-4063. PubMed ID: 36988752
    [No Abstract]   [Full Text] [Related]  

  • 108. The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer.
    Ashok Kumar P; Basnet A
    Transl Lung Cancer Res; 2023 Sep; 12(9):1838-1841. PubMed ID: 37854158
    [No Abstract]   [Full Text] [Related]  

  • 109. Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.
    Kubo T; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Kawai H; Ochi N; Oda N; Hara N; Hotta K; Tabata M; Maeda Y; Kiura K
    Respir Investig; 2023 Sep; 61(5):643-650. PubMed ID: 37480603
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.
    Attili I; Passaro A; Corvaja C; Trillo Aliaga P; Del Signore E; Spitaleri G; de Marinis F
    Cancer Treat Rev; 2023 Sep; 119():102602. PubMed ID: 37481836
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
    Borghetti P; Volpi G; Facheris G; Cossali G; Mataj E; La Mattina S; Singh N; Imbrescia J; Bonù ML; Tomasini D; Vitali P; Greco D; Bezzi M; Melotti F; Benvenuti M; Borghesi A; Grisanti S; Buglione di Monale E Bastia M
    Front Oncol; 2023; 13():1208204. PubMed ID: 37469420
    [TBL] [Abstract][Full Text] [Related]  

  • 112. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
    Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
    Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
    Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy.
    Nam JH; Yeo CD; Park CK; Kim SK; Kim JS; Kim YH; Kim JW; Kim SJ; Lee SH; Kang HS
    Thorac Cancer; 2023 Sep; 14(26):2657-2664. PubMed ID: 37519059
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy.
    Wang Y; Mathai J; Alamgeer M; Parakh S; Paul E; Mitchell P; Arulananda S
    JTO Clin Res Rep; 2023 Aug; 4(8):100544. PubMed ID: 37529402
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Severe cardiotoxicity induced by osimertinib in a patient with EGFR-mutated adenocarcinoma of the lung.
    Tanaka T; Nii S; Yamaoka H; Fujimoto N
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37479487
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.
    Langberg CW; Horndalsveen H; Helland Å; Haakensen VD
    Front Oncol; 2023; 13():1217424. PubMed ID: 37476372
    [TBL] [Abstract][Full Text] [Related]  

  • 118. First-line tremelimumab plus durvalumab and chemotherapy
    Liu W; Huo G; Chen P
    Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
    [No Abstract]   [Full Text] [Related]  

  • 119.
    Ogimoto T; Ozasa H; Yoshida H; Nomizo T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Yamazoe M; Ajimizu H; Tsuji T; Sakamori Y; Kuninaga K; Morita S; Hirai T
    Oncol Lett; 2023 Aug; 26(2):364. PubMed ID: 37545625
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
    Colombo N; Lorusso D; Monk BJ; Slomovitz B; Hasegawa K; Nogueira-Rodrigues A; Zale M; Okpara CE; Barresi G; McKenzie J; Makker V
    Oncologist; 2024 Jan; 29(1):25-35. PubMed ID: 37523661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.